What can we expect from dose escalation using proton beams?

Clinical Oncology

Volumn 15, Issue 1, 2003, Pages

  Fowler, J F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Intensity modulated radiation therapy; Normal tissue complications; Proton range; Tumour dose response

Indexed keywords

BEAM THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPLICATION; COMPUTER SYSTEM; CONTROLLED STUDY; DOSIMETRY; ELECTRON THERAPY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MODULATION; PARTICLE RADIATION; PHOTOTHERAPY; PRIORITY JOURNAL; PROSTATE TUMOR; PROTON RADIATION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION ENERGY; RADIATION RESPONSE; REVIEW; SAFETY; TREATMENT OUTCOME;

EID: 0037305953     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2002.0182     Document Type: Review

References (19)

1. Cozzi L. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol 2001;61:287-297.
2. Zurlo A, Lomax A, Hoess A, et al. The role of proton therapy in the treatment of large irradiation volumes: a comparative planning study of pancreatic and biliary tumors. Int J Radiat Oncol Biol Phys 2000;48:277-288.
3. Webb S, Nahum AE. A model for calculating tumor control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol 1993;38;653-666.
4. Mackie TR, Balog J, Ruchala K, et al. Tomotherapy. Semin Radiat Oncol 1999;9:108-117.
5. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-1105.
6. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-1116.
7. Goffman TE, Glatstein E. Intensity-modulated radiotherapy. Rad Res 2002;158:115-117.
8. Joiner MC, Marples B, Lambin P, Short SC, Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 2001;49:379-389.
9. Thames HD, Schultheiss TE, Hendry JH, et al. Can modest escalations of dose be detected as increased tumor control? Int J Radiat Oncol Biol Phys 1992;22:241-246.
10. Okunieff P, Morgan D, Niemierko A, Suit HD. Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys 1995;32:1227-1237.
11. Levegrün S, Jackson A, Zelefsky MJ, et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 2002;63:11-26.
12. Suit HD. The Gray Lecture 2001: Coming technical advances in radiation oncology. Int J Radiat Oncol Biol Phys 2002;53:798-809.
13. Brahme A. Dosimetric precision requirements in radiation therapy. Acta Radiol Oncol 1984;23:379-391.
14. Fowler JF, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021-1031.
15. Fowler JF, Ritter MA, Chappell RJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. (Submitted May 02).
16. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumour control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999;24:31-37.
17. Rosenman JG, Halle JS, Socinski MA et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348-356.
18. Blomgren H et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol 1995;34:861-870.
19. Fowler JF, Chappell R. Non small cell lung cancers repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000;46:516-517.